Posting of Annual Report and confirmation of AGM

Omega Diagnostics Group PLC
14 August 2023
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Posting of Annual Report and confirmation of AGM

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, confirms that the Notice of Annual General Meeting ('AGM') along with the Annual Report and Accounts for the year ended 31 March 2023 has been posted to shareholders on Friday afternoon and will shortly be made available on the Company's website at:

 

https://www.omegadiagnostics.com/Investor-Relations/Corporate-Information/Annual-Report-and-Interim-Results 

 

As previously announced, the AGM of the Company will be held on Wednesday 6 September 2023 at 11.00am at Poets House, St Mary's Street, Ely, CB7 4EY.

 

 

Contacts: 

 

Omega Diagnostics Group PLC                         

www.omegadx.com

Jag Grewal, Chief Executive Officer                            

via Walbrook PR

Chris Lea, Chief Financial Officer




finnCap Ltd                                              

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)


Nigel Birks / Harriet Ward (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303

Sam Allen

Mob: 07502 558 258



 

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 85 countries and is now focused on the health and nutrition sector.

 

www.omegadx.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings